radiotherapy Archives

Nuclidium and Actithera raise big in radiopharma

News and Trends 10 Jul 2025

Radiopharma’s new wave: Nuclidium and Actithera raise the stakes

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.

July 10, 2025 - 9 minutesmins - By Jules Adam

News and Trends 24 Feb 2025

Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?

This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues.

February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 28 Jan 2025

ITM-11 succeeds in phase 3: The first big win for radiopharma?

Discover ITM and its cancer candidate ITM-11, as it brings one of the first big wins the radiopharmaceutical sector awaits.

January 28, 2025 - 9 minutesmins - By Jules Adam

In Depth 26 Sep 2024

The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond

Delve into the world of radiopharmaceuticals: explore their mechanisms, promising candidates, and the key players driving innovation.

September 26, 2024 - 14 minutesmins - By Jules Adam

Podcast 23 Aug 2024

New German biotech spins out to develop radiotherapeutics

While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company

August 23, 2024

Podcast 5 Jul 2024

The radiotherapeutics boom

The field of radiotherapeutics is a hot topic currently. Listen to our conversation with three experts in the field.

July 5, 2024

News and Trends 13 Jun 2023

ITM follows €255M investment round by opening new facility

After a recent funding announcement, Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, has opened its new production facility for therapeutic radionuclides in Neufahrn near Munich, Germany. ITM’s new facility is the world’s largest production site of lutetium-177, an innovative medical isotope used in targeted cancer therapies. Due to its medical properties, lutetium-177 has […]

June 13, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 17 Mar 2023

How cancer cells repair DNA damage from radiotherapy

A team of scientists led by Kei-ichi Takata from the Center for Genomic Integrity (CGI) within the Institute for Basic Science (IBS) in South Korea, has discovered a new type of DNA repair mechanism that cancer cells use to recover from next-generation cancer radiation therapy. Ionizing radiation (IR) therapy is frequently used in the treatment […]

March 17, 2023 - 5 minutesmins - By Jim Cornall

glioblastoma oncolytic virus transgene 2

News and Trends 20 Jan 2023

New drug could replace current standard for treating brain cancer

Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in glioblastoma cells, identifying therapeutic targets to overcome radioresistance. […]

January 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Siddhartha Mukherjee, assistant professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division […]

December 9, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 6 Dec 2022

Startup Graegis developing therapies for radiation side-effects

Graegis Pharmaceuticals, a startup developing new therapies aimed at preventing the side effects of radiotherapies, is set to complete the regulatory nonclinical package allowing entry in clinical trials. The company, founded in the last quarter of 2021, spent the first year of operations running critical experiments on the new therapies, which will target radiation side […]

December 6, 2022 - 2 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

New radiopharmaceutical shrinks prostate cancer tumors

Researchers in Japan and Germany say a radiopharmaceutical treatment targeting a prostate-specific membrane antigen effectively shrinks prostate tumors in mice. The team reported the anti-cancer treatment zeroes in on tumor cells with ‘laser precision.’ Recent developments, such as targeted α-therapies as a type of theranostics, are trying to tackle cancer. Theranostics is a one-two punch […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

radiotherapy

Radiopharma’s new wave: Nuclidium and Actithera raise the stakes

Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?

ITM-11 succeeds in phase 3: The first big win for radiopharma?

The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond

New German biotech spins out to develop radiotherapeutics

The radiotherapeutics boom

ITM follows €255M investment round by opening new facility

How cancer cells repair DNA damage from radiotherapy

New drug could replace current standard for treating brain cancer

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Startup Graegis developing therapies for radiation side-effects

New radiopharmaceutical shrinks prostate cancer tumors

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!